Editorial

Treatment alert

Important new clinical data: potential early virologic failure associated with the combination antiretroviral regimen of tenofovir, ddI, and either efavirenz or nevirapine; Bristol-Myers Squib ‘Dear Healthcare Provider’ letter

Conference reports

6th International Workshop on Adverse Drug Reactions & Lipodystrophy in HIV

• Nucleoside analogue-related mitochondrial toxicity and link to lipoatrophy: effect of non-thymidine analogues (abacavir and tenofovir)
• Nucleosides reduce PPAR-gamma: a role for rosiglitazone without thymidine analogues?
• Potential for uridine to treat mitochondrial toxicity: still only in vitro data
• 25% patients take Kaletra on an empty stomach: dietary advice often missed at ‘centre of excellence’
• rHGH reduces central fat accumulation in adolescent lipodystrophy
• Weight loss is associated with elevated PBMC proviral DNA levels
• Coronary artery bypass graft is safe in HIV-positive patients but higher risk of longer term events
• Endothelial dysfunction similar in ARV-experienced and -naïve patients
• Pravastatin improves lipid profiles but not endothelial function
• Indinavir impairs endothelial function without insulin resistance
• Treatment interruptions improve lipids within four weeks: IL-2 has no metabolic effect
• Improvement of lipids following switch to tenofovir
• HCV coinfection linked to discontinuing ART due to toxicity
• Restorative treatments for HIV-associated lipoatrophy

44th Annual ICAAC

• Tipranavir in treatment experienced patients: results from RESIST-1
• Reverset: first data in patients with nucleoside resistance
• Poor response with tenofovir and ddI backbone causes early study termination
• Paradoxical CD4 response with tenofovir and ddI backbone
• Tenofovir/FTC backbone outperforms AZT/3TC (Combivir) with efavirenz in treatment naïve patients; reduced toxicity drives ITT viral efficacy
• Limited stability of lopinavir/r (Kaletra) above 25°C
• PK and drug interaction studies:
• Atorvastatin requires dose reduction with tipranavir/r
• Once-daily T-20 is less effective than twice daily: lower potency is related to C trough
• Further genetic link to efavirenz absorption
• Long-term response to FTC in children Is similar to adults
• Side effect update: hypersensitivity, heart, bones

55th Annual Meeting of the American Society for the Study of Liver Diseases (55th AASLD)

Treatment access

• Generic ARVs and WHO prequalification list
• Cotrimoxazole reduces mortality and morbidity in HIV-positive children: joint WHO/UNAIDS/UNICEF statement
• Equitable access for antiretroviral treatment for women

Antiretrovirals

• US guidelines updated
• Roche discontinue plans for nelfinavir 625mg formulation

Hepatitis coinfection

• Updated UK guidelines for HIV and Hepatitis coinfection
• IFN plus 3TC for coinfected patients

Other news

• ARV drug recycling project in UK

ON THE WEB

• Conference abstracts and reports
• Treatment Access
• Medical resources
• Journal articles online at Medscape
• Community resources and publications

PUBLICATIONS AND SERVICES FROM i-BASE

PUBLICATION ORDER FORM

Links to external websites are current at time of posting but not maintained.